chemokine environments to enhance local homing of immune effector cells and reduce the accumulation of regulatory/suppressive cells in tumor tissues; and 4) counteracting tumor-associated (or chronic infectionassociated) immune dysfunction. Dr. Kalinski’s work led to several current clinical trials of new cancer immunotherapies developed in collaboration with other members of the UPCI (colorectal-, prostate- and ovarian capittncers, melanoma, glioma and lymphoma). Dr. Kalinski currently serves as an IND sponsor of six clinical trials. Marina V. Kameneva Research Professor, Surgery and Bioengineering, McGowan Institute for Regenerative Medicine, University of Pittsburgh. PhD (Mechanical Engineering), School of Mathematics and Mechanics, Moscow State University, Moscow (former Soviet Union). After emigration to the United States, Dr. Kameneva joined the faculty of the University of Pittsburgh as a visiting scientist of the Artificial Heart and Lung Program and was appointed as a Research Assistant Professor of Surgery in 1996, as a Research Associate Professor of Surgery in 2000 and as Research Professor of Surgery and Bioengineering in 2006. Dr. Kameneva's areas of expertise are biorheology, hemorheology, macro and microhemodynamics, dragreducing polymers and their potential biomedical applications, and mechanical blood trauma in artificial organs. She is the author of near 150 peer reviewed publications as well as several book chapters in the areas of Fluid Mechanics and Biomechanics. Currently, as Director of the Hemorheology, Hemodynamics and Artificial Blood Research Laboratory, Dr. Kameneva is working with her research team on a variety of projects ranging from the testing of new medical devices to performing theoretical and experimental research related to novel treatments of acute and chronic ischemic conditions caused by disease or trauma, and development of next generation artificial organs including artificial blood. She is a PI, Co-PI and CoInvestigator of Federal grants. Karl Kandler Professor, Department of Otolaryngology (Primary), Neurobiology (secondary), Bioengineering (secondary). PhD University of Tübingen, Germany (1993). Dr. Kandler is the Director of the Auditory Research Group in the Department of Otolaryngology. His research uses live cell imaging and laser scanning photo stimulation to elucidate the cellular and synaptic mechanisms by which auditory neuronal circuits become reorganized during development and under pathological conditions (hearing loss, tinnitus). John A. Kellum, MD, FACP, MCCM Dr. John A. Kellum, MD, is Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical and Translational Science, and Vice Chair for Research within the Department of Critical Care Medicine and Director of the Center for Critical Care Nephrology at the University of Pittsburgh. Dr. Kellum received his medical degree from the Medical College of Ohio in 1984. His postgraduate training includes an internship and residency in Internal Medicine at the University of Rochester, NY, and a Fellowship in Critical Care Medicine at the University of Pittsburgh Medical Center. Dr. Kellum is actively involved in education, research and administration. Dr. Kellum’s research interests span various aspects of Critical Care Medicine, but center in critical care nephrology, sepsis and multi-organ failure, and clinical epidemiology, including consensus development and research methodology. He has authored more than 250 publications and has won several awards for teaching. He lectures widely and has given more than 300 seminars and invited lectures worldwide related to his research. Pratap Khanwilkar Professor and Coulter Program Director in the Department of Bioengineering, Executive-In-Residence, Pitt Innovation Institute and Professor in the McGowan Institute for Regenerative Medicine and in the Clinical and Translational Science Institute. PhD Bioengineering (Utah), MBA (Utah). Dr. Khanwilkar is a Fellow of the American Institute of Medical and Biological Engineering. As a serial medical device entrepreneur, he has started 6 medtech product/service companies, of which 3 are revenue-generating, one of which is a public company. He has taken a next-generation implantable LVAD from concept to First-In-Human
106